Insiders of Dianthus Therapeutics Getting Good Value On Their US$2.05m Investment
Insiders who bought Dianthus Therapeutics, Inc. (NASDAQ:DNTH) stock in the last 12 months were richly rewarded last week. The company's market value increased by US$177m as a result of the stock's 29%
Express News | Dianthus Therapeutics Shares Are Trading Higher After the Company Announced FDA. Clearance of Its Phase 2 Investigational New Drug Application for the MoMeNtum Trial of DNTH103 in Patients With Multifocal Motor Neuropathy
LifeSci Capital Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $45
LifeSci Capital analyst Rami Katkhuda maintains $Dianthus Therapeutics(DNTH.US)$ with a buy rating, and maintains the target price at $45.According to TipRanks data, the analyst has a success rate of
Dianthus Wins FDA Nod to Start Mid-stage Trial for Lead Asset
Express News | Dianthus Therapeutics Inc: Top-Line Results From Phase 2 Momentum Trial in Multifocal Motor Neuropathy Anticipated in 2H 2026
Express News | Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of Dnth103 in Multifocal Motor Neuropathy (Mmn)
LifeSci Capital Initiates Dianthus Therapeutics(DNTH.US) With Buy Rating, Announces Target Price $45
LifeSci Capital analyst Rami Katkhuda initiates coverage on $Dianthus Therapeutics(DNTH.US)$ with a buy rating, and sets the target price at $45.According to TipRanks data, the analyst has a success r
Wedbush Maintains Dianthus Therapeutics(DNTH.US) With Buy Rating, Maintains Target Price $38
Wedbush analyst Laura Chico maintains $Dianthus Therapeutics(DNTH.US)$ with a buy rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 45.3% and
Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference
NEW YORK and WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (NASDAQ:DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement
Dianthus Therapeutics Enhances Incentives and Affirms Governance
Companies Like Dianthus Therapeutics (NASDAQ:DNTH) Are In A Position To Invest In Growth
H.C. Wainwright Starts Dianthus as Buy, Cites Lead Drug Candidate
Analysts' Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics' DNTH103: A Potential Game-Changer in Autoimmune Disease Treatment
Express News | Dianthus Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $40
Dianthus Therapeutics (DNTH) Gets a Buy From Wedbush
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating
Dianthus Therapeutics (DNTH) has an average rating of buy and price targets ranging from $33 to $84, according to analysts polled by Capital IQ.
Express News | Dianthus Therapeutics Inc : Jefferies Cuts Target Price to $38 From $39
Express News | Dianthus Therapeutics Inc: Qtrly Shr Loss $0.54
Express News | Dianthus Therapeutics: Cash, Cash Equivalents and Short-Term Investments as of March 31, Projected to Provide Runway Into 2H 2027
No Data